Huaren Pharmaceutical: The application for the listing of isoproterenol hydrochloride chemical raw materials has been approved
Huaren Pharmaceutical's wholly-owned subsidiary Anhui Hengxing Pharmaceutical has received approval from the National Medical Products Administration for the market launch application of isoproterenol hydrochloride chemical raw materials. This drug is a non-selective β-adrenergic agonist, primarily used to treat cardiogenic or infectious shock, atrioventricular conduction block, cardiac arrest, and acute bronchial asthma attacks
According to the Zhitong Finance APP, Huaren Pharmaceutical (300110.SZ) announced that its wholly-owned subsidiary Anhui Hengxing Pharmaceutical Co., Ltd. (referred to as "Anhui Hengxing Pharmaceutical") has received the "Approval Notice for the Listing Application of Isoproterenol Hydrochloride" issued by the National Medical Products Administration.
Isoproterenol hydrochloride is a non-selective β-adrenergic receptor agonist that strongly stimulates β1 and β2 receptors, exhibiting powerful positive inotropic, positive chronotropic, and bronchodilator effects. Clinically, it is mainly used to treat cardiogenic or infectious shock, complete atrioventricular block, cardiac arrest, and acute attacks of bronchial asthma
